Research graph
References from Structure–interaction–performance relationships in quercetin-based co-amorphous systems: insights from molecular simulations and experimental characterization. Local targets link to admitted publications; unresolved targets remain external evidence.
CADD, AI and ML in drug discovery: a comprehensive review
10.1016/j.ejps.2022.106324 · 2023 · External reference
Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs
10.1016/j.ejpb.2024.114513 · 2024 · External reference
What is the true solubility advantage for amorphous pharmaceuticals?
10.1023/a:1007516718048 · 2000 · External reference
Physical stability of amorphous pharmaceutical solids: nucleation, crystal growth, phase separation and effects of the polymers
10.1016/j.ijpharm.2020.119925 · 2020 · External reference
Co-amorphous systems in drug delivery: Mechanistic insights, stability challenges, and future perspectives
2026 · External reference
Supersaturating drug delivery systems: the potential of co-amorphous drug formulations
10.1016/j.ijpharm.2017.08.123 · 2017 · External reference
Sulfasalazine–quercetin co-amorphous systems: sustained release behaviors and enhanced pharmacokinetics
10.1016/j.ejpb.2025.114972 · 2026 · External reference
Development and characterization of a spray-dried inhalable ternary combination for the treatment of P. aeruginosa biofilm infection in cystic fibrosis
10.1016/j.ejps.2023.106654 · 2024 · External reference
Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system
10.1016/j.ijpharm.2022.121657 · 2022 · External reference
10.1080/03639045.2022.2104308
10.1080/03639045.2022.2104308 · External reference
Dronedarone HCl – Quercetin Co-Amorphous System: Characterization and RP - HPLC Method Development for Simultaneous Estimation
10.1093/jaoacint/qsab024 · 2021 · External reference
Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs
10.3390/pharmaceutics13020171 · 2021 · External reference
The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer
10.1016/j.ijpharm.2019.118653 · 2019 · External reference
Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin
10.1016/j.ejpb.2014.12.025 · 2015 · External reference
Pellets containing quercetin amino acid co-amorphous mixture for the treatment of pain: Formulation, optimization, in-vitro and in-vivo study
2021 · External reference
Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers
10.1016/j.ejps.2020.105582 · 2021 · External reference
Interplay of solute crystallization and drying potential in controlling spray dried particle morphology
10.1016/j.ijpharm.2026.126744 · 2026 · External reference
Designing enhanced spray dried particles for inhalation: a review of the impact of excipients and processing parameters on particle properties
10.1016/j.powtec.2021.02.031 · 2021 · External reference
An efficient design strategy for flavonoid co-amorphous systems and enhanced their antioxidant and antibacterial activities for application potential in food preservation and functional products
10.1016/j.cej.2025.165093 · 2025 · External reference
Design of coamorphous systems for flavonoid components coformed with meglumine by integrating theory-model-experiment techniques
10.1021/acs.molpharmaceut.4c01536 · 2025 · External reference
Molecular simulation of polymer blend miscibility: a predictive thermodynamic framework anchored in Flory-Huggins interaction metrics
10.1080/08927022.2025.2567932 · 2025 · External reference
Molecular electrostatic potential: a new tool to predict the lithiation process of organic battery materials
10.1021/acs.jpclett.8b01123 · 2018 · External reference
Mechanistic insights into the crystallization of coamorphous drug systems
10.1016/j.jconrel.2023.01.019 · 2023 · External reference
Prediction of co-amorphous formation using non-bonded interaction energy: Molecular dynamic simulation and experimental validation
10.1016/j.ces.2023.118618 · 2023 · External reference
Negative mixing enthalpy route guides strong and ductile soft magnetic high-entropy alloys with high saturation magnetization
10.1016/j.mattod.2025.05.017 · 2025 · External reference
Cutting-edge approaches in the co-amorphization process
10.3390/pharmaceutics17070850 · 2025 · External reference
Assessing physical stability risk using the amorphous classification system (ACS) based on simple thermal analysis
10.1021/acs.molpharmaceut.9b00275 · 2019 · External reference
What are the important factors that influence API crystallization in miscible amorphous API–excipient mixtures during long-term storage in the glassy state?
10.1021/acs.molpharmaceut.1c00519 · 2022 · External reference
Structural analysis of molecular materials using the pair distribution function
10.1021/acs.chemrev.1c00237 · 2022 · External reference
Unresolved reference
2016 · External reference
Unresolved reference
External reference
Molecular structure and vibrational spectra of quercetin and quercetin-5’-sulfonic acid
10.1016/j.vibspec.2016.11.007 · 2017 · External reference
ATR-FTIR spectroscopy: its advantage and limitations
2002 · External reference
10.1007/978-981-33-6084-6_1
10.1007/978-981-33-6084-6_1 · External reference
Unresolved reference
2018 · External reference
Characteristics and significance of the amorphous state in pharmaceutical systems
10.1021/js9601896 · 1997 · External reference
Amorphous pharmaceutical solids: preparation, characterization and stabilization
2001 · External reference
On the thermodynamic thermal properties of quercetin and similar pharmaceuticals
10.3390/molecules27196630 · 2022 · External reference
Heat capacities of l-Arginine, l-Aspartic Acid, l-Glutamic Acid, l-Glutamine, and l-Asparagine
10.1007/s10765-021-02911-z · 2021 · External reference
Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion?
10.1016/j.ijpharm.2010.05.033 · 2010 · External reference
From atomic interactions to molecular miscibility and philicity: deciphering enthalpic driving forces
10.1021/acs.jpca.6c01567 · 2026 · External reference
Pharmaceutical solvates, hydrates and amorphous forms: a special emphasis on cocrystals
10.1016/j.addr.2017.03.002 · 2017 · External reference
Enhancement of water solubilization of quercetin by meglumine and application of the solubilization concept to a similar system
10.1016/j.molliq.2022.120756 · 2022 · External reference
10.1016/j.ejps.2018.07.046
10.1016/j.ejps.2018.07.046 · External reference
Designing a novel coamorphous salt formulation of telmisartan with amlodipine to enhance permeability and oral absorption
10.1021/acs.molpharmaceut.3c00226 · 2023 · External reference
Co-amorphization for solubility and dissolution rate improvement: the case of low-crystallization-tendency drugs
10.1007/s44446-026-00110-1 · 2026 · External reference
Influence of preparation methods on physicochemical and pharmacokinetic properties of co-amorphous formulations: the case of co-amorphous atorvastatin: naringin
10.1007/s12247-019-09381-9 · 2020 · External reference
Determination of the optimal molar ratio in amino acid-based coamorphous systems
10.1021/acs.molpharmaceut.0c00042 · 2020 · External reference
